BioNexus Gene Lab Corp. (BGLC) and Singapore-based Fidelion Diagnostics Pte Ltd have signed a term sheet for a strategic, cross-equity partnership. This alliance grants BGLC exclusive commercial rights to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) platform across Southeast Asia (ASEAN). BGLC will acquire a strategic equity stake in Fidelion, while Fidelion will receive an equity investment and a license fee from BGLC.
The VitaGuard™ platform is a tumor-naïve liquid biopsy MRD technology capable of detecting cancer recurrence at variant allele frequencies as low as 0.03%. This technology offers a significant advantage by not requiring prior tumor sequencing. The cost per test is expected to be under $300, a substantial reduction compared to current U.S. costs of approximately $3,000, making advanced MRD testing more accessible.
This alliance positions BGLC to capitalize on the growing precision oncology market in Southeast Asia, where cancer incidence is projected to reach 2.4 million new cases annually by 2030. The partnership aims to deliver next-generation cancer care to 680 million people across the region. The VitaGuard™ system is already commercialized in China by Tongshu Gene Biotechnology Co., Limited, the original developer of the technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.